

1. 認知症における行為の障害

認知症の進行とともに、新しい家電製品などの道具を使えなくなるが、取扱説明書の理解・記憶困難、健忘などによる手順の学習困難を原因とする使用行為の障害は失行に含めない。また、日常的に複数の道具や材料を用いて段階的に行う必要がある行為は naturalistic action と呼ばれ、その障害は、左半球損傷に限らず、右半球損傷、外傷性脳損傷、認知症⁵⁾で広く認められる。認知症では、このような段階的行為の1つ1つのステップに失行の特徴が認められないことも多く、系列的に行為を処理するのに必要な注意の容量が低下していることが原因であることも少なくない。

2. 上肢の失行

上肢の失行は、誤る行為の種類で分類するか、誤りの誤反応タイプで分類するかなどについて、いくつかの考え方があり。表2に上肢の失行の分類を整理した。観念運動失行は、行為時の動作の空間的・時間的誤反応がみられるものをいう。大脳皮質基底核変性症(corticobasal degeneration ; CBD)では、行為の種類や実施方法によらず古典的な観念運動失行に相当する障害が多くみられる⁶⁾。単一の道具(とその対象物)の使用行為については、

目標と違う道具を使う動作に置換された場合を概念的誤反応とし、「概念失行」と呼ぶ場合がある。概念失行の最初の検討は、AD例で報告された⁷⁾。図5に示すように、失行の責任病巣としては頭頂葉と前頭葉の重要性が指摘されている。

3. 肢節運動失行

主に手と指による行為の遂行が、不完全、粗雑、途切れ途切れとなった(拙劣な)状態であり、運動麻痺、錐体外路症状、失調、感覚障害が原因と考えられないものをいう¹⁾。母指で同じ手の他の指先を順番に触るというような指の運動、机の上に置いた硬貨、マッチ棒、鉛筆などをつかむ、紐を結ぶ、お札を数える、本のページをめくるなど細かい手の動作が拙劣となる。上述の失行と異なる点は、中心溝周囲の手の領域の不全損傷によって、対側の手に症状が現れる点である。肢節運動失行は、CBDの症状が明らかな手において、経過の一時期に認められることがある。

4. Alien hand

CBDを特徴づける上肢の異常動作として alien hand が挙げられることがある⁸⁾。Alien hand はさまざまな意

表2 失行の分類

		古典分類	行為の種類による分類	誤反応による分類**	
				時間的・空間的誤反応	概念的誤反応
行為の種類	象徴的行為	観念運動失行	パントマイム失行	(観念運動失行)	
	道具使用のパントマイム			観念運動失行	概念失行
	道具の使用	観念運動失行または観念失行*	使用失行		

*古典分類では、道具の使用における失行を観念運動失行に分類する立場と観念失行に分類する立場がある。

**誤反応による分類は、道具使用の身振りにおける誤りを対象としているが、実際の使用にも適用できる。象徴的行為は対象としない。

パントマイム失行と使用失行は、行為の種類に基づいた分類である。しかし、パントマイム失行では時間的空間的誤反応が、使用失行では概念的誤反応が多いというニュアンスもある。




図5 上肢の失行の責任病巣

頭頂葉と前頭葉の病巣が重視されている。頭頂間溝周囲と中前頭回付近(ピンク色の領域)を重視する報告と、もう少し下方の領域(緑上回から角回付近と下前頭回、灰色の領域)を重視する報告がある。

味合いで用いられるので、その内容を明記することが重要である。CBDでは、しばしばなんらかの刺激や動作を誘引として起こる不随意な(意図的でない)上肢動作を指してalien handと呼んでいることが多い。脳梁離断でみられる拮抗失行のように右手と反対目的の行為を左手が行ったり、左前大脳動脈領域脳梗塞で前頭葉内側面と脳梁前部を損傷した場合に右手が道具の強迫的使用を行ったりする場合のように、目的のある行為を意図に反して行うalien handとは異なる。

V 失 認

1. 本来の失認

失認とは、特定の感覚モダリティを通して呈示された物品の認知障害であり、感覚障害、他の高次脳機能障害、未知性などに帰することができないものをいう¹⁾。失認は、感覚モダリティによって、視覚失認、聴覚失認、触覚失認などが生じるほか、相貌失認のようにカテゴリー特異的なものもある。

視覚失認は、後頭-側頭葉底面の病巣ないしは後大脳動脈領域脳梗塞で起こることが多い(図6)。この観点からいえば、SPECTで後頭葉の血流低下が特徴的なレビー

小体型認知症(dementia with Lewy bodies ; DLB)で視覚失認が起こってもよさそうである。実際に、DLBではさまざまな視覚の障害があり、幻視、妄想性誤認、視覚失認、視覚性構成障害の一因となっているという報告がある⁹⁾。しかし、認知症全体において、物を見て何であるかがわからないという典型的な視覚失認が前景に立つことは少なく、緩徐進行性の視覚失認例の報告¹⁰⁾などが散見される程度である。

聴覚失認では、進行性非流暢性失語や意味性認知症での合併例があるほか、緩徐進行性に大脳性難聴を呈した症例の報告¹¹⁾もある。

2. 相貌に関する問題

相貌失認は、十分な視力・視野は保たれているが、熟知した顔を見て名前がいえただけでなく、誰だかわからない症状である。声を聞けば誰であるかがわかり、有名な(熟知した)名前を聞けばどのような人物かを述べられる。病巣は、右紡錘状回の側頭-後頭移行部付近が必須病巣(図7)と考えられるが、典型的かつ持続性となるのは両側病変が多い。

進行性相貌失認として報告されている例のうち、一部は紡錘状回の萎縮が示されているが¹²⁾、多くは右側頭葉(前部)の下外側部に病変が想定されている。すなわち、非言語性側面での意味性認知症に近い病態と考えられ¹³⁾、相貌や名前に対する意味記憶の障害が想定される。

3. 道順障害

地誌的見当識障害は、見渡せる範囲を超えて移動する際に道に迷う症状である。この構成要素のうち、建物や風景の失認にあたる街並失認は、前述の視覚失認同様に認知症初期の際立った症状としての報告は見当たらない。一方で、前向き健忘によって新しい道順を覚えられないのではなく、熟知した場所でも道に迷う症状が現れれば「道順障害」と考えられる。責任病巣としては脳梁膨大後域から楔前部下部が重視されており¹⁴⁾、ADでの脳血流低下部位と対応する。したがって、ADでの道迷いには道順障害が関与している可能性も考えられる。




図6 連合型視覚失認と相貌失認の病巣
右半球の紡錘状回または両側の紡錘状回の付近の病巣で相貌失認が、左半球の紡錘状回または両側の紡錘状回の付近の病巣で連合型視覚失認が起こる。小さな楕円で、fMRI による検討から推定された、物体の形態処理に関わる外側後頭複合体(lateral occipital complex ; LOC), 顔の認知に関わる紡錘状回顔領域(fusiform face area ; FFA), 顔の形態処理に関わる後頭顔領域(occipital face area ; OFA)を示した。




図7 空間性注意のネットワークと半側空間無視を起こす病巣
下頭頂小葉(縁上回, 角回)と上縦束または視床への連絡路, ならびに下前頭回後部と上縦束または視床への連絡路の2つのタイプの病巣が半側空間無視の代表的病巣である。その他, 内包後脚など視床と頭頂葉などを結ぶ白質の損傷でも半側空間無視が生じる。

Ⅵ 空間性注意障害

空間性注意の外界に対するバランスが崩れ、一側への偏りが生じた状態が半側空間無視と考えられる¹⁾。脳血管障害では、右側頭頭頂葉から前頭葉の病巣により(図7)、左無視のかたちで現れる。ADは大脳後方領域の機能低下から始まることが多いが、必ずしも左右均等に進行するとは限らない。SPECTで右側頭頭頂領域の血流低下が優位なAD患者は、線分二等分試験で左半側空間無視を示すことがある¹⁵⁾。

ADの亜型として起こることがある posterior cortical atrophy¹⁶⁾では、後頭頭頂葉の萎縮や血流低下が目立ち、記憶障害に先立って背側型同時失認(視覚性注意障害)をはじめとする Bálint 症候群を呈することが多い。背側型同時失認では、注意の向いた方向で対象がうまく捉えられた場合に、主に視野中心部で単一の物体を認知できても、周囲のものがみつからない。

Ⅵ 遂行機能障害

遂行機能(executive function)とは、言語、行為、対象の認知、記憶など、ある程度独立性をもった高次脳機能を制御し統合する「より高次の」機能である¹⁾。遂行機能障害では、目標を定め、計画を立て、必要な方略を適宜使い、同時進行で起こるさまざまな出来事を処理し、周囲の状況変化に柔軟に追従し、長期的な展望で、持続性をもって、行動することのいずれか、または複数が障害される。遂行機能において重要な役割を果たしているのは、前頭葉のうち前頭前野である。FTDや皮質下血管性認知症で遂行機能障害が目立りがちであるが、ADでも遂行機能障害がみられ、鑑別に用いるのは難しい¹⁷⁾。

Ⅶ おわりに

いわゆる「巣症状」の症状、発現機序、病巣について概説したが、今日では、皮質領域に白質神経路を加えたネットワークとしての機能とその障害という考え方で高次脳機能を捉えるようになってきている。神経ネット

ワークの機能に関する理解が進むと同時に、認知症の病変の進行についても、脳の皮質における好発部位というよりも神経ネットワークとしての傷害されやすさという捉え方に変化してきている。神経ネットワークとしてみると、言語にしても空間性注意にしても、後方領域のみ、あるいは前方領域のみで機能していることはなく、より大きなスケールで機能している。認知症で見られる、いわゆる巣症状についても、より脳全体の機能を見渡して、変性との関連を理解するように努める必要がある。

文 献

- 1) 石合純夫：高次脳機能障害学。東京，医歯薬出版，2003
- 2) Seelaar H, Rohrer JD, Pijnenburg YA, et al : Clinical, genetic and pathological heterogeneity of frontotemporal dementia : A review. *J Neurol Neurosurg Psychiatry* **82** : 476-486, 2011
- 3) Agosta F, Henry RG, Migliaccio R, et al : Language networks in semantic dementia. *Brain* **133** : 286-299, 2010
- 4) Gorno-Tempini ML, Hillis AE, Weintraub S, et al : Classification of primary progressive aphasia and its variants. *Neurology* **76** : 1006-1014, 2011
- 5) Giovannetti T, Libon DJ, Buxbaum LJ, et al : Naturalistic action impairments in dementia. *Neuropsychologia* **40** : 1220-1232, 2002
- 6) Stamenova V, Roy EA, Black SE : A model-based approach to understanding apraxia in corticobasal syndrome. *Neuropsychol Rev* **19** : 47-63, 2009
- 7) Ochipa C, Rothi LJ, Heilman KM : Conceptual apraxia in Alzheimer's disease. *Brain* **115** : 1061-1071, 1992
- 8) FitzGerald DB, Drago V, Jeong Y, et al : Asymmetrical alien hands in corticobasal degeneration. *Mov Disord* **22** : 581-584, 2007
- 9) Mori E, Shimomura T, Fujimori M, et al : Visuoperceptual impairment in dementia with Lewy bodies. *Arch Neurol* **57** : 489-493, 2000
- 10) Giovagnoli AR, Aresi A, Reati F, et al : The neuropsychological and neuroradiological correlates of slowly progressive visual agnosia. *Neurol Sci* **30** : 123-131, 2009
- 11) 李英愛, 石合純夫, 綿引定清, 他 : 緩徐進行性の脳性難聴と語間代を呈した神経変性症の1例. *神心理* **17** : 54-61, 2001
- 12) Joubert S, Felician O, Barbeau E, et al : Impaired configurational processing in a case of progressive prosopagnosia associated with predominant right temporal lobe atrophy. *Brain* **126** : 2537-2550, 2003
- 13) Snowden JS, Thompson JC, Neary D : Knowledge of famous faces and names in semantic dementia. *Brain* **127** : 860-872, 2004
- 14) 高橋伸佳, 河村満 : 街並失認と道順障害. *神研の進歩* **39** : 689-696, 1995
- 15) Ishiai S, Koyama Y, Seki K, et al : Unilateral spatial neglect in AD : Significance of line bisection performance. *Neurology* **55** : 364-370, 2000
- 16) McMonagle P, Deering F, Berliner Y, et al : The cognitive profile of posterior cortical atrophy. *Neurology* **66** : 331-338, 2006
- 17) Giovagnoli AR, Erbetta A, Reati F, et al : Differential neuropsychological patterns of frontal variant frontotemporal dementia and Alzheimer's disease in a study of diagnostic concordance. *Neuropsychologia* **46** : 1495-1504, 2008

Glucose tolerance status and risk of dementia in the community

The Hisayama Study

T. Ohara, MD
Y. Doi, MD, PhD
T. Ninomiya, MD, PhD
Y. Hirakawa, MD
J. Hata, MD, PhD
T. Iwaki, MD, PhD
S. Kanba, MD, PhD
Y. Kiyohara, MD, PhD

Address correspondence and reprint requests to Dr. Yutaka Kiyohara, Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
kiyohara@envmed.med.kyushu-u.ac.jp

ABSTRACT

Objective: We investigated the association between glucose tolerance status defined by a 75-g oral glucose tolerance test (OGTT) and the development of dementia.

Methods: A total of 1,017 community-dwelling dementia-free subjects aged ≥ 60 years who underwent the OGTT were followed up for 15 years. Outcome measure was clinically diagnosed dementia.

Results: The age- and sex-adjusted incidence of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD) were significantly higher in subjects with diabetes than in those with normal glucose tolerance. These associations remained robust even after adjustment for confounding factors for all-cause dementia and AD, but not for VaD (all-cause dementia: adjusted hazard ratio [HR] = 1.74, 95% confidence interval [CI] = 1.19 to 2.53, $p = 0.004$; AD: adjusted HR = 2.05, 95% CI = 1.18 to 3.57, $p = 0.01$; VaD: adjusted HR = 1.82, 95% CI = 0.89 to 3.71, $p = 0.09$). Moreover, the risks of developing all-cause dementia, AD, and VaD significantly increased with elevated 2-hour postload glucose (PG) levels even after adjustment for covariates, but no such associations were observed for fasting plasma glucose (FPG) levels: compared with those with 2-hour PG levels of < 6.7 mmol/L, the multivariable-adjusted HRs of all-cause dementia and AD significantly increased in subjects with 2-hour PG levels of 7.8 to 11.0 mmol/L or over, and the risk of VaD was significantly higher in subjects with levels of ≥ 11.1 mmol/L.

Conclusions: Our findings suggest that diabetes is a significant risk factor for all-cause dementia, AD, and probably VaD. Moreover, 2-hour PG levels, but not FPG levels, are closely associated with increased risk of all-cause dementia, AD, and VaD. *Neurology*® 2011;77:1126-1134

GLOSSARY

AD = Alzheimer disease; **CI** = confidence interval; **DSM-III-R** = *Diagnostic and Statistical Manual of Mental Disorders*, 3rd edition, revised; **FPG** = fasting plasma glucose; **HR** = hazard ratio; **IFG** = impaired fasting glycemia; **IGT** = impaired glucose tolerance; **NGT** = normal glucose tolerance; **OGTT** = oral glucose tolerance test; **PG** = postload glucose; **VaD** = vascular dementia.

Diabetes mellitus is one of the most common metabolic disorders, and its prevalence has risen globally in recent years. Some epidemiologic studies have reported that diabetes is independently implicated in the development of dementia.¹⁻³ However, these findings are inconsistent for its subtypes; one study found an association between diabetes and the risk of both Alzheimer disease (AD) and vascular dementia (VaD),¹ whereas other studies found an association with only AD^{2,3} or only VaD,⁴⁻⁷ and still others showed no association between diabetes and either condition.^{8,9} These conflicting results may have been related to differences in the study designs, including the defined criteria for diabetes and dementia subtypes, as well as in the regional characteristics and ethnicities of the settings and subjects. Thus, accurate definitions of diabetes and dementia subtypes are needed to ascertain the true associations between the two, and a 75-g oral glucose tolerance test (OGTT) and morphologic examination of the brain may meet this requirement. However, to date, very few cohort studies have had enough quality data to allow reliable diagnosis using these methods.

Supplemental data at
www.neurology.org

Supplemental Data



From the Departments of Environmental Medicine (T.O., Y.D., T.N., Y.H., J.H., Y.K.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (Y.D., T.N., Y.H., J.H.), and Neuropathology (T.I.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Study funding: Supported in part by Grants-in-Aid for Scientific Research (nos. 20591063, 21590698, 22590892, and 22300116) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a Health and Labour Sciences Research Grant of the Ministry of Health, Labour and Welfare of Japan (Comprehensive Research on Aging and Health: H20-Chouju-004).

Disclosure: Author disclosures are provided at the end of the article.

To resolve these issues, we performed a prospective cohort study of dementia in a Japanese community-dwelling population, all members of which underwent the OGTT. The most important feature of this study is that the subtypes of dementia were verified by detailed neurologic and morphologic examination, including neuroimaging and autopsy. Using data from this cohort study, we investigated the association between glucose tolerance levels defined by the OGTT and the development of dementia and its subtypes.

METHODS Study population. A population-based prospective study of cerebro-cardiovascular diseases was begun in 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area of Kyushu Island in Japan. In addition, comprehensive surveys of cognitive impairment in the elderly of this town have been conducted since 1985. In 1988, a total of 1,228 residents aged ≥ 60 years (91.1% of the total population in this age group) participated in a screening examination for the present study. After exclusion of 33 subjects who had dementia, 90 who had already had breakfast, 5 who were on insulin therapy, and 81 who could not complete the OGTT, a total of 1,019 subjects without dementia underwent the OGTT. From a total of 1,019 subjects, 2 who died before starting follow-up were excluded, and the remaining 1,017 subjects (437 men and 580 women) were enrolled in this study.

Follow-up survey. The subjects were followed up prospectively for 15 years, from December 1988 to November 2003 (mean 10.9 years; SD 4.1 years). A complete description of the follow-up survey is provided in appendix e-1 on the *Neurology*[®] Web site at www.neurology.org.

Diagnosis of dementia. The diagnosis of dementia was made based on the guidelines of the *DSM-III-R*.¹⁰ Subjects diagnosed with AD met the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria¹¹ and subjects diagnosed with VaD met the National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.¹² Possible or probable dementia subtypes were diagnosed with clinical information including neuroimaging. Definite dementia subtypes were also determined on the basis of clinical and neuropathologic information. The diagnostic procedure for autopsy cases was reported previously.¹³ A neuropathologic diagnosis of AD was made following the National Institute on Aging–Reagan Institute criteria,¹⁴ where the frequency of neuritic plaques and neurofibrillary tangles was evaluated using the Consortium to Establish a Registry for Alzheimer’s Disease criteria¹⁵ and Braak stage.¹⁶ Definite VaD cases were confirmed with causative stroke or cerebrovascular change and no neuropathologic evidence of other forms of dementia. Every dementia case was adjudicated by expert psychiatrists.

During the follow-up, 232 subjects (79 men and 153 women) developed dementia. Of these, 201 (86.6%) were evaluated by brain imaging, and 118 (50.9%) underwent brain autopsy; in 110, both were performed. Thus, 209 subjects in all (90.1%) had some kind of morphologic examination. Among the 118 autopsy cases, the clinical diagnosis of 42 cases (35.6%)

was changed by the neuropathologic findings. Among all dementia cases, 18 AD cases and 11 VaD cases had other coexisting subtypes of dementia. These cases were counted as events in the analysis for other dementia. In all, 105 cases were categorized as AD, 65 as VaD, and 62 as other dementia.

Risk factor measurement. At the baseline examination, we performed the OGTT after an at least 12-hour overnight fast. Plasma glucose levels were determined by the glucose-oxidase method. Glucose tolerance status was defined by the 1998 WHO criteria¹⁷: normal glucose tolerance (NGT), fasting plasma glucose (FPG) < 6.1 and 2-hour postload glucose (PG) < 7.8 ; impaired fasting glycemia (IFG), FPG 6.1 to 6.9 and 2-hour PG < 7.8 ; impaired glucose tolerance (IGT), FPG < 7.0 and 2-hour PG 7.8 to 11.0; and diabetes, FPG ≥ 7.0 mmol/L or 2-hour PG ≥ 11.1 mmol/L. Each of the FPG and 2-hour PG level was also divided into 4 categories (FPG: < 5.6 , 5.6 to 6.0, 6.1 to 6.9, and ≥ 7.0 mmol/L; 2-hour PG: < 6.7 , 6.7 to 7.7, 7.8 to 11.0, and ≥ 11.1 mmol/L).

In order to assess the independent effects of glucose tolerance levels on dementia occurrence, the following baseline factors in addition to age and sex were used as confounding factors: 1) information on smoking habits, alcohol intake, and physical activity was obtained by means of a questionnaire administered to each subject; 2) a low education level was defined as ≤ 6 years of formal education; 3) history of stroke was determined on the basis of all clinical data available in the Hisayama Study; 4) hypertension was defined as blood pressure levels $\geq 140/90$ mm Hg or current treatment with antihypertensive agents; 5) EKG abnormalities were defined as left ventricular hypertrophy (Minnesota Code 3-1), ST depression (4-1, 2, or 3) or atrial fibrillation (8-3); 6) serum total cholesterol levels were measured enzymatically; and 7) body mass index (kg/m^2) and waist to hip ratio were used as indicators of obesity.

Statistical analysis. The SAS software package, version 9.2 (SAS Institute, Cary, NC), was used to perform all statistical analyses. Age- and sex-adjusted mean values of possible risk factors were calculated by the analysis of covariance method. Frequencies of risk factors were adjusted for age and sex by the direct method. The differences in the mean values and frequencies of risk factors between NGT and other glucose tolerance levels were tested using Fisher least significant difference method and logistic regression analysis, respectively. The incidence of dementia was calculated by the person-years method and was adjusted for age and sex by the direct method using 5-year age groups of the overall study population; the differences among glucose tolerance levels and trends across FPG and 2-hour PG levels were tested using Cox proportional hazards model. The adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) were also calculated using the Cox proportional hazards model. Missing values of waist to hip ratio ($n = 27$) and education ($n = 12$) were replaced with the means in the multivariate analysis. The population attributable fraction of combined category of IGT and diabetes for dementia was calculated using the following equation with the observed multivariate-adjusted HR of the combined category and its frequency in event cases (P_e)¹⁸:

$$\text{PAF} = P_e (\text{HR} - 1) / \text{HR}$$

Two-sided $p < 0.05$ was considered statistically significant in all analyses.

Standard protocol approvals, registrations, and patient consents. This study was conducted with the approval of the Kyushu University Institutional Review Board for Clinical Re-

Table 1 Age- and sex-adjusted mean values or frequencies of potential risk factors for dementia according to the 1998 WHO criteria: The Hisayama Study, 1988^a

	Normal glucose tolerance (n = 559)	Impaired fasting glycemia (n = 73)	Impaired glucose tolerance (n = 235)	Diabetes (n = 150)	No. of missing values
Age, y, mean (SD)	68 (6)	70 (6) ^b	69 (6)	69 (6)	0
Men, %	40.8	52.1	43.8	45.3	0
Fasting plasma glucose, mmol/L, mean (SD)	5.3 (0.9)	6.4 (0.9) ^c	5.8 (0.9) ^c	7.7 (0.9) ^c	0
Two-hour postload glucose, mmol/L, mean (SD)	5.9 (2.2)	5.9 (2.2)	8.9 (2.2) ^c	14.9 (2.2) ^c	0
Systolic blood pressure, mm Hg, mean (SD)	133 (21)	141 (21) ^c	143 (21) ^c	145 (21) ^c	0
Diastolic blood pressure, mm Hg, mean (SD)	75 (10)	76 (10)	78 (10) ^c	77 (10) ^b	0
Hypertension, % ^d	43.8	66.7 ^c	63.2 ^c	62.2 ^c	0
Electrocardiogram abnormalities, %	20.6	31.7	18.8	21.6	0
Body mass index, kg/m ² , mean (SD)	21.8 (3.0)	22.2 (3.0)	23.2 (3.0) ^c	23.2 (3.0) ^c	0
Waist to hip ratio, cm/cm, mean (SD)	0.91 (0.07)	0.93 (0.07) ^b	0.93 (0.07) ^c	0.94 (0.07) ^c	27
Total cholesterol, mmol/L, mean (SD)	5.3 (1.1)	5.5 (1.1)	5.4 (1.1)	5.7 (1.1) ^c	0
History of stroke at entry, %	3.3	3.5	5.9	6.3	0
Education \leq 6 y, %	10.3	12.5	13.9	11.3	12
Smoking, %	23.5	23.8	23.5	22.7	0
Alcohol intake, %	23.4	29.0	27.7	34.8 ^c	0
Physical activity, %	20.2	22.8	16.8	14.7	0

^a Mean age was sex adjusted. Percentage of men was age adjusted. Electrocardiogram abnormalities were defined as Minnesota Code 3-1, 4-1, 4-2, 4-3, or 8-3.

^b $p < 0.05$ vs normal glucose tolerance.

^c $p < 0.01$ vs normal glucose tolerance.

^d Hypertension: blood pressure \geq 140/90 mm Hg or current use of antihypertensive agents.

search, and written informed consent was obtained from the participants.

RESULTS Table 1 shows the age- and sex-adjusted mean values or frequencies of risk factors for dementia by the WHO criteria at baseline. Compared with those with NGT, the mean values of systolic and diastolic blood pressures, body mass index, waist to hip ratio, and total cholesterol, and the frequencies of hypertension and alcohol intake, were higher in subjects with IFG, IGT, or diabetes.

The age- and sex-adjusted incidences and adjusted HRs of all-cause dementia and its subtypes according to glucose tolerance status defined by the WHO criteria are shown in table 2. Compared with those with NGT, the age- and sex-adjusted incidence and HR of all-cause dementia were significantly higher in subjects with IGT as well as those with diabetes. This association remained unchanged in subjects with diabetes even after adjustment for age, sex, hypertension, EKG abnormalities, body mass index, waist to hip ratio, total cholesterol, history of stroke at entry, education, smoking habits, alcohol intake, and physical activity. In regard to subtypes of dementia, the age- and sex-adjusted incidence and

adjusted HRs of AD were significantly higher in subjects with diabetes than in those with NGT. The age- and sex-adjusted incidence and HR of VaD were significantly increased in subjects with IGT or diabetes compared with those with NGT; however, these associations were not significant after multivariable adjustment. No significant associations were observed between glucose tolerance levels and the risk of other dementia. When IGT and diabetes were brought together in one category, this category also had the significantly higher risks of all-cause dementia, AD, and VaD in the age- and sex-adjusted analysis, and these associations remained significant for all-cause dementia and AD even after adjustment for other possible risk factors. The population attributable fraction of this combined category was 14.6% for all-cause dementia, 20.1% for AD, and 17.0% for VaD.

Table 3 presents the associations between FPG levels and adjusted risks of all-cause dementia and its subtypes. The age- and sex-adjusted incidences and HRs of all-cause dementia and any of the dementia subtypes did not differ among FPG levels. This tendency was unchanged even in the multivariate analysis. Conversely, as shown in table 4, the age- and

Table 2 Age- and sex-adjusted incidence and adjusted hazard ratios and their 95% confidence intervals for the development of all-cause dementia and its subtypes according to glucose tolerance status defined by WHO criteria

Glucose tolerance level	Person-years at risk, n	No. of events, n	Age- and sex-adjusted incidence	Crude HR (95% CI)	p	Age- and sex-adjusted HR (95% CI)	p	Multivariable-adjusted ^a HR (95% CI)	p
All-cause dementia									
Normal	6,658	115	20.1	1 (referent)		1 (referent)		1 (referent)	
IFG	854	13	16.0	0.89 (0.50-1.58)	0.70	0.74 (0.42-1.31)	0.30	0.63 (0.35-1.13)	0.12
IGT	2,611	63	24.9	1.46 (1.07-1.99)	0.02	1.40 (1.03-1.91)	0.03	1.35 (0.98-1.86)	0.07
DM	1,544	41	29.3	1.62 (1.14-2.32)	0.008	1.71 (1.19-2.44)	0.003	1.74 (1.19-2.53)	0.004
IGT + DM	4,155	104	26.3	1.52 (1.17-1.98)	0.002	1.51 (1.16-1.97)	0.002	1.46 (1.10-1.92)	0.008
Alzheimer disease									
Normal	6,658	51	8.6	1 (referent)		1 (referent)		1 (referent)	
IFG	854	5	6.6	0.77 (0.31-1.94)	0.58	0.63 (0.25-1.57)	0.32	0.61 (0.24-1.55)	0.29
IGT	2,611	29	11.7	1.53 (0.97-2.41)	0.07	1.46 (0.92-2.30)	0.11	1.60 (0.99-2.59)	0.05
DM	1,544	20	14.2	1.81 (1.08-3.03)	0.03	1.94 (1.16-3.26)	0.01	2.05 (1.18-3.57)	0.01
IGT + DM	4,155	49	12.5	1.63 (1.10-2.41)	0.01	1.62 (1.10-2.40)	0.02	1.73 (1.15-2.60)	0.009
Vascular dementia									
Normal	6,658	27	5.1	1 (referent)		1 (referent)		1 (referent)	
IFG	854	6	7.1	1.76 (0.73-4.26)	0.21	1.40 (0.58-3.41)	0.46	1.01 (0.41-2.52)	0.98
IGT	2,611	20	7.8	1.95 (1.09-3.47)	0.02	1.86 (1.05-3.32)	0.04	1.39 (0.76-2.54)	0.29
DM	1,544	12	8.7	2.00 (1.01-3.95)	0.04	2.07 (1.05-4.09)	0.04	1.82 (0.89-3.71)	0.09
IGT + DM	4,155	32	7.9	1.97 (1.18-3.29)	0.01	1.94 (1.16-3.23)	0.01	1.54 (0.90-2.63)	0.11
Other dementia									
Normal	6,658	37	6.4	1 (referent)		1 (referent)		1 (referent)	
IFG	854	2	2.2	0.42 (0.10-1.75)	0.23	0.36 (0.09-1.51)	0.16	0.34 (0.08-1.44)	0.14
IGT	2,611	14	5.5	0.99 (0.54-1.84)	0.99	0.96 (0.52-1.78)	0.90	0.94 (0.49-1.78)	0.84
DM	1,544	9	6.5	1.08 (0.52-2.24)	0.83	1.10 (0.53-2.28)	0.80	1.19 (0.56-2.52)	0.66
IGT + DM	4,155	23	5.8	1.03 (0.61-1.73)	0.92	1.01 (0.60-1.70)	0.97	0.97 (0.57-1.67)	0.91

Abbreviations: CI = confidence interval; DM = diabetes mellitus; HR = hazard ratio; IFG = impaired fasting glycemia; IGT = impaired glucose tolerance.

^a Multivariate adjustment was made for age, sex, hypertension, electrocardiogram abnormalities, body mass index, waist to hip ratio, total cholesterol, history of stroke at entry, education, smoking habits, alcohol intake, and physical activity.

sex-adjusted incidences and HRs of all-cause dementia, AD, and VaD significantly increased with rising 2-hour PG levels. Compared with those with 2-hour PG levels of <6.7 mmol/L, the age- and sex-adjusted incidences and HRs of all-cause dementia, AD, and VaD were marginally or significantly higher in subjects with 2-hour PG levels of 7.8 to 11.0 mmol/L and significantly higher in subjects with 2-hour PG levels of ≥ 11.1 mmol/L. These associations remained robust even after multivariable adjustment; the risks of all-cause dementia and AD were significantly increased in subjects with 2-hour PG levels of 7.8 to 11.0 mmol/L and over, and the risk of VaD was significantly higher in those with 2-hour PG levels of ≥ 11.1 mmol/L.

Sensitivity analysis in which only definite cases of dementia determined by brain autopsy were used as

event cases did not make any material difference in these findings, except with respect to VaD, for which the significant association disappeared, probably due to the few event cases (table 5). When only clinical diagnoses were used for cases with both clinical and neuropathologic diagnoses, the findings were substantially unchanged, though the HRs became slightly lower probably due to the decreased accuracy of diagnosis (tables e-1, e-2, and e-3).

DISCUSSION In a long-term prospective study of an elderly Japanese population, we demonstrated that diabetes that was assessed 15 years earlier was a significant risk factor for the development of all-cause dementia, AD, and VaD. Moreover, the risks of developing all-cause dementia and its sub-

Table 3 Age- and sex-adjusted incidence and adjusted hazard ratios and their 95% confidence intervals for the development of all-cause dementia and its subtypes according to fasting plasma glucose levels

Fasting plasma glucose levels	Person-years at risk, n	No. of events, n	Age- and sex-adjusted incidence	Crude HR (95% CI)	p	Age- and sex-adjusted HR (95% CI)	p	Multivariable-adjusted ^a HR (95% CI)	p
All-cause dementia									
<5.6	5,589	101	20.7	1 (referent)		1 (referent)		1 (referent)	
5.6-6.0	3,286	71	25.1	1.24 (0.91-1.68)	0.17	1.21 (0.89-1.64)	0.22	1.18 (0.86-1.61)	0.31
6.1-6.9	1,724	39	21.6	1.13 (0.91-1.91)	0.14	1.13 (0.78-1.64)	0.52	0.96 (0.65-1.41)	0.82
≥7.0	1,067	21	22.3	1.21 (0.70-1.79)	0.64	1.14 (0.71-1.82)	0.60	1.21 (0.75-1.96)	0.44
				p for trend: 0.23		p for trend: 0.42		p for trend: 0.63	
Alzheimer disease									
<5.6	5,589	48	10.1	1 (referent)		1 (referent)		1 (referent)	
5.6-6.0	3,286	30	10.3	1.11 (0.70-1.74)	0.67	1.14 (0.72-1.80)	0.58	1.11 (0.69-1.77)	0.68
6.1-6.9	1,724	16	9.1	1.15 (0.65-2.02)	0.64	1.00 (0.57-1.77)	0.99	0.99 (0.49-1.64)	0.72
≥7.0	1,067	11	11.9	1.23 (0.64-2.37)	0.53	1.29 (0.67-2.48)	0.45	1.41 (0.72-2.76)	0.32
				p for trend: 0.47		p for trend: 0.56		p for trend: 0.58	
Vascular dementia									
<5.6	5,589	24	4.9	1 (referent)		1 (referent)		1 (referent)	
5.6-6.0	3,286	19	6.7	1.38 (0.76-2.52)	0.29	1.29 (0.71-2.36)	0.41	1.19 (0.64-2.19)	0.58
6.1-6.9	1,724	17	8.7	2.40 (1.29-4.47)	0.006	1.93 (1.03-3.61)	0.04	1.48 (0.77-2.84)	0.24
≥7.0	1,067	5	5.2	1.12 (0.43-2.93)	0.82	1.10 (0.42-2.89)	0.84	0.99 (0.37-2.69)	0.99
				p for trend: 0.10		p for trend: 0.19		p for trend: 0.49	
Other dementia									
<5.6	5,589	29	5.7	1 (referent)		1 (referent)		1 (referent)	
5.6-6.0	3,286	22	8.1	1.33 (0.76-2.31)	0.32	1.27 (0.73-2.21)	0.40	1.21 (0.68-2.16)	0.51
6.1-6.9	1,724	6	3.8	0.69 (0.29-1.67)	0.42	0.60 (0.25-1.45)	0.26	0.53 (0.22-1.31)	0.17
≥7.0	1,067	5	5.2	0.92 (0.36-2.37)	0.86	0.91 (0.35-2.36)	0.85	1.02 (0.39-2.67)	0.97
				p for trend: 0.68		p for trend: 0.53		p for trend: 0.52	

Abbreviations: CI = confidence interval; HR = hazard ratio.

^a Multivariate adjustment was made for age, sex, hypertension, electrocardiogram abnormalities, body mass index, waist to hip ratio, total cholesterol, history of stroke at entry, education, smoking habits, alcohol intake, and physical activity.

types progressively increased with elevating 2-hour PG levels.

In prior prospective epidemiologic studies, there have been conflicting results regarding the associations between diabetes and incidences of all-cause dementia and AD, while the influence of diabetes on the risk of VaD has been positive in most studies.^{1,4-7} Cohort studies in which diabetes was defined by nonfasting blood glucose levels or clinical information did not reveal clear associations of diabetes with the development of all-cause dementia and AD,⁴⁻⁸ while the risks of dementia and its subtypes significantly increased in diabetes in some studies, most of which defined diabetes using the OGTT.¹⁻³ The latter findings were in accord with ours. This fact suggests that differences in the methods used to define diabetes lead to a discrepancy in the association be-

tween diabetes and the risk of dementia, especially AD, and that an OGTT is essential for the definition of diabetes in epidemiologic studies on the diabetes-dementia association.

In our study, the incidence of VaD was significantly higher in subjects with IGT or diabetes than in those with NGT, but this association disappeared after adjustment for other covariates. This might occur due to the few VaD cases. In addition, since other known cardiovascular risk factors, such as hypertension, obesity, and dyslipidemia, accumulate under a prediabetic or diabetic state, as shown in our data (table 1), IGT and diabetes seem to increase the risk of VaD through mediation of these risk factors, especially hypertension.

In the present study, increased 2-hour PG levels including a prediabetic range were significantly

Table 4 Age- and sex-adjusted incidence and adjusted hazard ratios and their 95% confidence intervals for the development of all-cause dementia and its subtypes according to 2-hour postload glucose levels

2-Hour postload glucose levels	Person-years at risk, n	No. of events, n	Age- and sex-adjusted incidence	Crude HR (95% CI)	p	Age- and sex-adjusted HR (95% CI)	p	Multivariable-adjusted ^a HR (95% CI)	p
All-cause dementia									
<6.7	5,354	85	17.6	1 (referent)		1 (referent)		1 (referent)	
6.7-7.7	2,277	44	20.9	1.20 (0.84-1.73)	0.32	1.25 (0.87-1.80)	0.24	1.16 (0.78-1.71)	0.47
7.8-11.0	2,844	67	24.7	1.53 (1.11-2.11)	0.009	1.54 (1.12-2.12)	0.009	1.50 (1.07-2.11)	0.02
≥11.1	1,192	36	32.8	2.08 (1.41-3.07)	<0.001	2.32 (1.57-3.44)	<0.001	2.47 (1.62-3.77)	<0.001
				p for trend: <0.001		p for trend: <0.001		p for trend: <0.001	
Alzheimer disease									
<6.7	5,354	37	7.6	1 (referent)		1 (referent)		1 (referent)	
6.7-7.7	2,277	20	8.8	1.25 (0.73-2.16)	0.41	1.23 (0.71-2.12)	0.46	1.49 (0.83-2.67)	0.17
7.8-11.0	2,844	30	11.3	1.59 (0.98-2.57)	0.06	1.56 (0.96-2.53)	0.07	1.87 (1.13-3.12)	0.02
≥11.1	1,192	18	15.8	2.44 (1.39-4.29)	0.002	2.75 (1.56-4.85)	<0.001	3.42 (1.83-6.40)	<0.001
				p for trend: 0.002		p for trend: <0.001		p for trend: <0.001	
Vascular dementia									
<6.7	5,354	21	4.6	1 (referent)		1 (referent)		1 (referent)	
6.7-7.7	2,277	12	6.3	1.33 (0.65-2.70)	0.43	1.49 (0.73-3.04)	0.27	1.14 (0.54-2.41)	0.73
7.8-11.0	2,844	20	7.2	1.83 (0.99-3.38)	0.05	1.87 (1.01-3.45)	0.04	1.38 (0.72-2.64)	0.34
≥11.1	1,192	12	11.2	2.75 (1.35-5.60)	0.005	3.15 (1.55-6.43)	0.002	2.66 (1.24-5.70)	0.01
				p for trend: 0.004		p for trend: 0.002		p for trend: 0.02	
Other dementia									
<6.7	5,354	27	5.4	1 (referent)		1 (referent)		1 (referent)	
6.7-7.7	2,277	12	5.8	1.04 (0.52-2.04)	0.92	1.08 (0.55-2.15)	0.82	0.86 (0.40-1.84)	0.70
7.8-11.0	2,844	17	6.2	1.21 (0.66-2.23)	0.53	1.21 (0.66-2.23)	0.53	1.14 (0.60-2.16)	0.69
≥11.1	1,192	6	5.8	1.05 (0.44-2.55)	0.91	1.12 (0.46-2.71)	0.81	1.21 (0.48-3.04)	0.69
				p for trend: 0.65		p for trend: 0.59		p for trend: 0.59	

Abbreviations: CI = confidence interval; HR = hazard ratio.

^a Multivariate adjustment was made for age, sex, hypertension, electrocardiogram abnormalities, body mass index, waist to hip ratio, total cholesterol, history of stroke at entry, education, smoking habits, alcohol intake, and physical activity.

linked to elevated risks of all-cause dementia, AD, and VaD, but no such associations were observed for FPG. The epidemiologic evidence from Asia has also indicated that 2-hour PG levels are better in detecting prediabetes and diabetes compared with FPG levels.¹⁹ However, very few prospective studies have investigated the associations between FPG as well as 2-hour PG levels and the risks of dementia and its subtypes. Only the Uppsala Longitudinal Study of Adult Men evaluated the associations of FPG levels with the risks of developing AD and VaD,^{20,21} and this study concluded that increased FPG levels were not risk factors for these subtypes of dementia. This is in good agreement with our findings. The Uppsala Study²¹ and the Honolulu-Asia Aging Study¹ also found no clear associations between 2-hour PG levels and the risks of AD and VaD. These findings are

inconsistent with ours. Our recent clinicopathologic study of deceased Hisayama residents revealed that higher levels of 2-hour PG but not of FPG were clearly associated with increased risk for formation of neuritic plaques even after adjustment for confounding factors.²² This evidence together with the findings of the present study suggests that elevated 2-hour PG levels play an important role in the formation of neuritic plaques, and thereby in the development of AD. Meanwhile, it is well known that increased 2-hour PG levels are closely associated with the development of stroke, which is well established as a main cause of VaD. Thus, it is reasonable to postulate a close association between 2-hour PG levels and the risk of VaD.

Possible pathophysiologic mechanisms through which diabetes or elevated blood glucose levels might

Table 5 Age- and sex-adjusted hazard ratios and their 95% confidence intervals for the development of all-cause dementia and its subtypes determined by autopsy according to 2-hour postload glucose levels

2-Hour postload glucose levels	Person-years at risk, n	No. of events, n	Crude HR (95% CI)	p	Age- and sex-adjusted HR (95% CI)	p
All-cause dementia						
<6.7	5,354	47	1 (referent)		1 (referent)	
6.7-7.7	2,277	23	1.14 (0.69-1.88)	0.61	1.24 (0.75-2.05)	0.39
7.8-11.0	2,844	29	1.19 (0.75-1.89)	0.47	1.20 (0.76-1.91)	0.44
≥11.1	1,192	19	1.94 (1.14-3.31)	0.01	2.24 (1.31-3.83)	0.003
			p for trend: 0.04		p for trend: 0.02	
Alzheimer disease						
<6.7	5,354	12	1 (referent)		1 (referent)	
6.7-7.7	2,277	7	1.35 (0.53-3.44)	0.53	1.40 (0.55-3.56)	0.48
7.8-11.0	2,844	12	1.94 (0.87-4.33)	0.10	1.92 (0.86-4.26)	0.11
≥11.1	1,225	8	3.27 (1.34-8.00)	0.009	3.88 (1.58-9.53)	0.003
			p for trend: 0.009		p for trend: 0.005	
Vascular dementia						
<6.7	5,354	17	1 (referent)		1 (referent)	
6.7-7.7	2,277	8	1.09 (0.47-2.54)	0.83	1.23 (0.53-2.86)	0.63
7.8-11.0	2,844	8	0.90 (0.39-2.09)	0.81	0.92 (0.40-2.12)	0.84
≥11.1	1,192	7	1.98 (0.82-4.77)	0.13	2.32 (0.96-5.61)	0.06
			p for trend: 0.36		p for trend: 0.26	
Other dementia						
<6.7	5,354	18	1 (referent)		1 (referent)	
6.7-7.7	2,277	8	1.04 (0.45-2.39)	0.93	1.17 (0.51-2.70)	0.72
7.8-11.0	2,844	9	0.96 (0.43-2.14)	0.92	0.98 (0.44-2.19)	0.97
≥11.1	1,192	4	1.04 (0.35-3.07)	0.95	1.16 (0.39-3.43)	0.79
			p for trend: 0.99		p for trend: 0.88	

Abbreviations: CI = confidence interval; HR = hazard ratio.

affect the initiation and promotion of dementia have been extensively discussed in a number of studies.²³ A recent review summarized 4 major pathways for hyperglycemia-induced dementia: namely, atherosclerosis, microvascular disease, glucose toxicity leading to the accumulation of advanced protein glycation and increased oxidative stress, and changes in insulin metabolism resulting in an insulin-resistant state and distorted amyloid metabolism in the brain.²³ The former 2 pathways are considered to be involved in the development of VaD, while the latter 2 pathways may mainly contribute to the development of AD. Additionally, recent evidence has emerged to imply that vascular factors may be involved in AD.²³ It is reported that 2-hour PG values can be a good marker of oxidative stress levels arising from hyperglycemia^{24,25} and correlate with insulin resistance.²⁶ Higher oxidative stress and insulin resistance may precede the accumulation of amyloid- β peptide and neurofibrillary tangles^{23,27} and accelerate arteriosclerosis in the brain,²⁸ resulting in increased risk of AD and VaD. It is known that Asians have

lower levels of insulin secretion compared with other ethnic groups²⁹ and can develop diabetes, insulin resistance, and metabolic syndrome with lower body mass index levels.³⁰ These findings suggest that hyperglycemia plays a larger role in the development of dementia compared with insulin resistance in Asians including Japanese. Further studies are needed to elucidate the pathogenesis of hyperglycemia and diabetes in the development of dementia.

The strengths of our study include its longitudinal population-based study design, use of OGTT for determination of glucose tolerance levels in all subjects, long duration of follow-up, perfect follow-up of subjects, and morphologic examination of the brains of most dementia cases with autopsy and neuroimaging. Several limitations of our study should be noted. First, the diagnosis of glucose tolerance status was based on a single measurement of glucose levels at baseline, as was the case in most other epidemiologic studies. During the follow-up, risk factor levels were changed due to modifications in lifestyle or medication especially in subjects with diabetes, and

misclassification of glucose tolerance categories was possible. This could have weakened the association found in this study, biasing the results toward the null hypothesis. Therefore, the true association may be stronger than that shown here. Second, some subjects ($n = 33$ to 65) did not participate in the follow-up surveys of cognitive function performed in 1992, 1998, and 2005, and their cognitive conditions were evaluated only by mail or telephone. This might have resulted in failure to detect dementia cases. However, we also collected information on the development of dementia in another way, namely through the daily monitoring system established in the town. Thus, we believe that we detected almost all dementia cases, and this bias did not affect our findings. Third, the diagnosis of dementia was verified by autopsy only in 50.9% of dementia cases, resulting in a certain degree of subtype misclassification; agreement rate between clinical diagnosis and neuropathologic diagnosis was not high (64.4%) in our autopsy cases of dementia. However, a sensitivity analysis using only definite cases of dementia determined by brain autopsy did not make any material difference in our findings.

Our findings emphasize the need to consider diabetes as a potential risk factor for all-cause dementia, AD, and probably VaD. The other main finding, that elevated 2-hour PG levels are closely associated with increased risks of all-cause dementia and its subtypes, supports the view that postprandial glucose regulation is critical to prevent future dementia. Further investigations are required to clarify the associations between 2-hour PG levels by the OGTT and subtypes of dementia in other ethnic populations.

AUTHOR CONTRIBUTIONS

Tomoyuki Ohara contributed to the study concept, design, data collection, endpoint adjudication, interpretation of data, statistical analysis, and writing the manuscript. Yasufumi Doi contributed to the study concept, design, interpretation of data, statistical analysis, and writing the manuscript. Toshiharu Ninomiya contributed to the data collection, endpoint adjudication, interpretation of data, and statistical analysis. Yoichiro Hirakawa and Jun Hata contributed to data collection and interpretation of data. Toru Iwaki and Shigenobu Kanba contributed to endpoint adjudication and interpretation of data. Yutaka Kiyohara is a study coordinator and contributed to the study performance, obtaining supporting sources, study concept, design, endpoint adjudication, interpretation of data, and writing of manuscript. All authors critically reviewed the manuscript and approved final version.

ACKNOWLEDGMENT

The authors thank the staff of the Division of Health and Welfare of Hisayama for their cooperation in this study.

DISCLOSURE

Dr. Ohara, Dr. Doi, Dr. Ninomiya, Dr. Hirakawa, and Dr. Hata report no disclosures. Dr. Iwaki serves as an editorial board member of *Neuropathology*, *Brain Tumor Pathology*, and *Pathology-Research and Practice* and is funded by a Grant-in-Aid for Scientific Research (B) from Japan Society for the Promotion of Science (JSPS). Dr. Kanba serves as a scientific board

member of Astellas Pharma Inc. and an editorial board member of *Molecular Psychiatry*, *Journal of Neuroscience and Psychiatry*, *Asian Journal of Psychiatry*, and *Asia Pacific Journal of Psychiatry*, has received honoraria from Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, Asahi Kasei Kuraray Medical Co., Ltd., and Shionogi & Co., Ltd.; and receives research support from Ono Pharmaceutical Co. Ltd. and Grant from Japanese Ministry of Education and of Health. Dr. Kiyohara is funded by a Health and Labour Sciences Research Grant of the Ministry of Health, Labour and Welfare of Japan (Comprehensive Research on Aging and Health: H20-Chouju-004).

Received February 4, 2011. Accepted in final form May 25, 2011.

REFERENCES

1. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. *Diabetes* 2002;51:1256–1262.
2. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. *Neurology* 1999;53:1937–1942.
3. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. *Am J Epidemiol* 1997;145:301–308.
4. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. *Diabetologia* 2009;52:1031–1039.
5. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. *Am J Epidemiol* 2001;154:635–641.
6. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. *Dement Geriatr Cogn Disord* 2002;14:77–83.
7. Hassing LB, Johansson B, Nilsson SE, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. *Int Psychogeriatr* 2002;14:239–248.
8. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. *Arch Neurol* 2006;63:1551–1555.
9. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE $\epsilon 4$: the Cardiovascular Health Study Cognition Study. *Arch Neurol* 2008;65:89–93.
10. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 3rd ed, revised. Washington, DC: American Psychiatric Association; 1987.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939–944.
12. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. report of the NINDS-AIREN International Workshop. *Neurology* 1993;43:250–260.
13. Fujimi K, Sasaki K, Noda K, et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama Study. *Brain Pathol* 2008;18:317–325.

14. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. *Neurobiol Aging* 1997;18:S1-S2.
15. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479-486.
16. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991;82:239-259.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-553.
18. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. *Am J Public Health* 1998;88:15-19.
19. Qiao Q, Nakagami T, Tuomilehto J, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. *Diabetologia* 2000;43:1470-1475.
20. Rönnemaa E, Zethelius B, Sundelöf J, et al. Impaired insulin secretion increases the risk of Alzheimer disease. *Neurology* 2008;71:1065-1071.
21. Rönnemaa E, Zethelius B, Sundelöf J, et al. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men. *Diabetologia* 2009;52:1504-1510.
22. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama Study. *Neurology* 2010;75:764-770.
23. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. *Lancet Neurol* 2006;5:64-74.
24. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA* 2006;295:1681-1687.
25. Wolever TMS, Chiasson JL, Csima A, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. *Diabetes Care* 1998;21:336-340.
26. Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. *Metabolism* 2006;55:1263-1281.
27. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol* 2001;60:759-767.
28. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. *Circulation* 2002;106:1211-1218.
29. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID study group. β -Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. *Diabetes* 2002;51:2170-2178.
30. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. *Metabolism* 2004;53:831-835.

CELEBRATING 80 YEARS
OF PUBLICATION

Neurology

Historical Abstract: February 1, 1989

CORRELATION OF MAGNETIC RESONANCE IMAGING WITH NEUROPSYCHOLOGICAL TESTING IN MULTIPLE SCLEROSIS

S. M. Rao, G. J. Leo, V. M. Haughton, P. St. Aubin-Faubert, and L. Bernardin

Neurology 1989;39:161-166

Previous research has suggested that cerebral lesions observed on magnetic resonance imaging (MRI) of MS patients are clinically "silent." We examined the validity of this assertion by correlating neuropsychological test performance with MRI findings in 53 MS patients. We used a semiautomated quantitation system to measure three MRI variables: total lesion area (TLA), ventricular-brain ratio (VBR), and size of the corpus callosum (SCC). Stepwise multiple regression analyses indicated that TLA was a robust predictor of cognitive dysfunction, particularly for measures of recent memory, abstract/conceptual reasoning, language, and visuospatial problem solving. SCC predicted test performance on measures of mental processing speed and rapid problem solving, while VBR did not independently predict cognitive test findings. These findings suggest that cerebral lesions in MS produce cognitive dysfunction and that MRI may be a useful predictor of cognitive dysfunction.

Free Access to this article at www.neurology.org/content/39/2/161

Comment from Richard M. Ransohoff, MD, Associate Editor: A pioneering study showing that MS-related cognitive impairment correlated with MRI changes, and thus arose directly from the disease process.

Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

N-Terminal Pro-Brain Natriuretic Peptide and Risk of Cardiovascular Events in a Japanese Community : The Hisayama Study

Yasufumi Doi, Toshiharu Ninomiya, Jun Hata, Yoichiro Hirakawa, Naoko Mukai, Fumie Ikeda, Masayo Fukuhara, Masanori Iwase and Yutaka Kiyohara

Arterioscler Thromb Vasc Biol. 2011;31:2997-3003; originally published online September 15, 2011;

doi: 10.1161/ATVBAHA.111.223669

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2011 American Heart Association, Inc. All rights reserved.

Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/content/31/12/2997>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:
<http://atvb.ahajournals.org/subscriptions/>

N-Terminal Pro-Brain Natriuretic Peptide and Risk of Cardiovascular Events in a Japanese Community

The Hisayama Study

Yasufumi Doi, Toshiharu Ninomiya, Jun Hata, Yoichiro Hirakawa, Naoko Mukai, Fumie Ikeda, Masayo Fukuhara, Masanori Iwase, Yutaka Kiyohara

Objective—Few studies have examined the association between natriuretic peptides and the incidence of cardiovascular disease (CVD) in Asian populations.

Methods and Results—A total of 3104 community-dwelling Japanese individuals aged ≥ 40 years without history of CVD were followed up for 5 years. A total of 127 CVD events were identified. The age- and sex-adjusted incidence of CVD increased with increasing N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (< 55 , 55 – 124 , 125 – 399 , and ≥ 400 pg/mL) at baseline and was significantly higher even in subjects with a modest increase. This association remained robust even after adjustment for other potential risk factors (55 – 124 pg/mL: multivariate-adjusted hazard ratio = 1.85 [95% CI 1.07 – 3.18], $P = 0.03$; 125 – 399 pg/mL: 2.98 [95% CI 1.65 – 5.39], $P < 0.001$; ≥ 400 pg/mL: 4.54 [95% CI 2.22 – 9.29], $P < 0.001$). The multivariate-adjusted hazard ratios for the development of total CVD and its subtypes, coronary heart disease and stroke, were significantly increased by a 1 SD increment of the log NT-proBNP concentrations and were nearly equal among CVD subtypes. Similar findings were observed for stroke subtypes of ischemic stroke and intracerebral hemorrhage but not subarachnoid hemorrhage. The effects of the 1 SD increment in log NT-proBNP values were comparable in subjects with and without other cardiovascular risk factors, except for sex. The area under the receiver operating characteristic curve was significantly ($P = 0.006$) increased by adding NT-proBNP values to the model including other potential risk factors.

Conclusion—Elevated NT-proBNP levels were shown to be a significant risk factor for the development of CVD and its subtypes in a general Japanese population, independently of other cardiovascular risk factors. (*Arterioscler Thromb Vasc Biol.* 2011;31:2997-3003.)

Key Words: coronary artery disease ■ epidemiology ■ risk factors ■ stroke ■ cohort study

B-type natriuretic peptide (BNP) is a cardiac hormone secreted from the myocardium in response to increased ventricular stretch and wall tension. The precursor of BNP is split equimolarly into a biologically active peptide and a more stable N-terminal fragment (N-terminal pro-BNP [NT-proBNP]).^{1,2} Measurement of circulating BNP or NT-proBNP levels has been recommended in the diagnosis and prognosis of patients with symptoms of left ventricular dysfunction³ and for stratification of prognosis in patients with acute coronary syndromes.^{4,5} Several prospective studies of community-dwelling persons have focused on the association between BNP/NT-proBNP and the risk of cardiovascular disease (CVD), particularly in white populations.^{6–11} However, it is not certain to what extent these findings apply to general Asian populations. In addition, to the best of our knowledge, no studies have evaluated the association between BNP/NT-proBNP levels and hemorrhagic stroke, which has pathophys-

iological mechanisms different from those of thrombotic diseases.

The objective of the current study was to examine the associations between NT-proBNP levels at baseline and the development of CVD and its subtypes in a general Japanese population, taking into account comprehensive confounders.

Methods

Study Population

A population-based prospective study of CVD and its risk factors has been under way since 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area on Japan's Kyushu Island. The age, occupational distributions, and nutritional intake of the population were almost identical to those of the general Japanese population, based on data from the national census and nutrition survey.¹² In 2002, a baseline survey for the present study was performed in the town. A detailed description of this survey was published previously.¹³ Briefly, of all residents aged ≥ 40 years, 3328 underwent

Received on: January 18, 2011; final version accepted on: August 25, 2011.

From the Departments of Medicine and Clinical Science (Y.D., T.N., J.H., Y.H., N.M., F.I., M.F., M.I.) and Environmental Medicine (Y.D., T.N., J.H., Y.H., N.M., F.I., M.F., Y.K.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Correspondence to Yasufumi Doi, MD, PhD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail doi@intmed2.med.kyushu-u.ac.jp

© 2011 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.111.223669

Downloaded from <http://atvb.ahajournals.org> at University of Tsukuba on March 13, 2013

examination (participation rate, 77.6%). A total of 224 individuals were subsequently excluded from the study; among these, 30 subjects did not consent to participate in the study, 190 had a history of CVD, and 4 had an insufficient quantity of stored sera for NT-proBNP measurement. Overall, 3104 individuals (1303 men and 1801 women) were enrolled in the study.

Follow-Up Survey

The subjects were followed up prospectively for 5 years, from 2002 to 2007, by repeated health examinations. The health status was checked yearly by mail or telephone for subjects who did not undergo a regular examination or who had moved away from town. We also established a daily monitoring system among the study team, local physicians, and members of the town's Health and Welfare Office. Using this system, we gathered information on new CVD events, including suspected cases. When coronary heart disease or stroke occurred or was suspected, physicians in the study team examined the subject and evaluated his or her detailed clinical information. The clinical diagnosis of coronary heart disease or stroke was based on the patient's history, physical and neurological examinations, and ancillary laboratory examinations. Additionally, when a subject died, an autopsy was performed at the Department of Pathology of Kyushu University. During the follow-up period, no subject was lost to follow-up, and 192 subjects died, of whom 129 (67.2%) underwent autopsy.

Definition of End Points

The outcomes of the present analysis were incidence and mortality of CVD. Total CVD was diagnosed as the development of coronary heart disease and stroke, and CVD death was defined as I00 to I99 of International Classification of Diseases-10.

The diagnosis and classification of stroke were determined on the basis of clinical information, including brain computed tomography and magnetic resonance imaging, cerebral angiography, echocardiography, carotid duplex imaging, and autopsy findings.¹⁴ In principle, stroke was defined as a sudden onset of nonconvulsive and focal neurological deficit persisting for >24 hours. Stroke was further divided into ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage based on the Classification of Cerebrovascular Disease III proposed by the National Institute of Neurological Disorders and Stroke.¹⁵

The criteria for the diagnosis of coronary heart disease included acute and silent myocardial infarction, sudden cardiac death within 1 hour after the onset of acute illness, coronary artery angioplasty, and bypass grafting. The diagnosis of myocardial infarction was based on detailed clinical information and at least 2 of the following findings: typical clinical symptoms; ECG evidence of myocardial infarction; elevated cardiac enzymes; and morphological findings, including echocardiographic, scintigraphic, or angiographic abnormalities compatible with myocardial injury, and autopsy findings. Silent myocardial infarction was defined as myocardial scarring without any historical indication of clinical symptoms or abnormal cardiac enzyme changes.

During the follow-up, 127 first-ever CVD events (77 men and 50 women) and 48 CVD deaths occurred. Among the CVD events, there were 49 cases of coronary heart disease (36 cases of myocardial infarction, 8 of coronary artery angioplasty, 2 of coronary artery bypass grafting, and 3 of sudden cardiac death) and 83 of stroke (54 cases of ischemic stroke, 19 of intracerebral hemorrhage, 9 of subarachnoid hemorrhage, and 1 of unclassified stroke).

Clinical Evaluation and Laboratory Measurement

At the screening examination, a portion of a serum specimen was stored at -80°C until it was used for the measurement of NT-proBNP concentrations in 2009. NT-proBNP levels were measured using a second-generation commercial kit, the Elecsys proBNP Immunoassay,¹⁶ on an Elecsys 2010 platform.

Serum creatinine was measured by the enzymatic method using a fresh blood sample. The estimated glomerular filtration rate (eGFR)

was calculated using the following modified equation of the Modification of Diet in Renal Disease Study for Japanese¹⁷:

$$\begin{aligned} \text{eGFR (mL/min per } 1.73 \text{ m}^2) &= 0.808 \times 175 \times \\ &(\text{serum creatinine [mg/dL]})^{-1.154} \times (\text{age [years]})^{-0.203} \times \\ &(0.741 [\text{Japanese coefficient}]) \times (0.742 \text{ if female}). \end{aligned}$$

Urine creatinine and albumin were measured using a spot urine sample by the turbidimetric immunoassay method. The urine albumin-creatinine ratio (mg/g) was calculated by dividing the urinary albumin values by the urinary creatinine concentrations. Chronic kidney disease was defined as an eGFR of <60 mL/min per 1.73 m² or a urine albumin-creatinine ratio of ≥30 mg/g according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines.¹⁸ Plasma glucose concentrations were determined by the glucose-oxidase method. Diabetes was defined as fasting glucose concentrations ≥7.0 mmol/L, 2-hour postload or postprandial glucose concentrations ≥11.1 mmol/L, or taking antidiabetic medications. Total and high-density lipoprotein cholesterol levels were determined enzymatically, and hypercholesterolemia was defined as a total cholesterol level of ≥5.69 mmol/L.

Blood pressure was obtained 3 times using an automated sphygmomanometer (BP-203RV III, Colin, Tokyo, Japan) with the subject in a sitting position; the average of the 3 measurements was used in the present analysis. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or current treatment with antihypertensive agents. ECG abnormalities were defined as left ventricular hypertrophy (Minnesota Code 3-1), ST depression (4-1, 4-2, or 4-3), or atrial fibrillation (8-3).

Height and weight were measured with the subject wearing light clothes without shoes, and body mass index (BMI) (kg/m²) was calculated. Obesity was defined as a BMI level of ≥25 kg/m². Each participant completed a self-administered questionnaire covering medical history, smoking habits, alcohol intake, and exercise. Smoking habits and alcohol intake were classified as either current habitual use or not. Those subjects who were engaged in sports or other forms of exertion ≥3 times a week during their leisure time made up a regular exercise group.

Statistical Analysis

NT-proBNP levels were divided into 4 categories: <55, 55 to 124, 125 to 399, and ≥400 pg/mL according to the prior reports.^{3,19,20} Age- and sex-adjusted mean values for possible risk factors were calculated by analysis of covariance, and their trends across NT-proBNP levels were tested by multiple regression analysis. Frequencies of risk factors were adjusted for age and sex by the direct method and were examined for trends by the Cochran-Mantel-Haenszel test. The incidence of CVD was calculated by the person-year method and was adjusted for age and sex by the direct method using 10-year age groupings. The age- and sex-adjusted or multivariate-adjusted hazard ratios (HRs) and their 95% CIs were calculated using Cox proportional hazards model. The linear trends of HRs across NT-proBNP levels were also tested using the Cox proportional hazards model. Comparisons of the effects of increased NT-proBNP values between participants with and without other cardiovascular risk factors were made by adding an interaction term to the statistical model. To compare the accuracy of risk assessment for CVD development between the models adjusted for potential risk factors with and without NT-proBNP values, receiver operating characteristic (ROC) curves for the model were plotted. The consistency in the area under the ROC curve between the models was estimated using the method of DeLong et al.²¹ All analyses were performed using the SAS software package version 9.2 (SAS Institute Inc, Cary, NC). Values of *P*<0.05 were considered statistically significant in all analyses.

Ethical Considerations

This study was conducted with the approval of the Kyushu University Institutional Review Board for Clinical Research, and written informed consent was obtained from all the participants.

Table 1. Age- and Sex-Adjusted Mean Values or Frequencies of Possible Risk Factors According to NT-proBNP Levels at Baseline, 2002

Risk Factor*	NT-proBNP levels (pg/ml)				P value
	<55 (n=1606)	55–124 (n=915)	125–399 (n=444)	≥400 (n=139)	
Age, y	55 (9)	64 (11)	73 (11)	78 (11)	<0.001
Men, %	49.6	32.7	32.2	46.0	<0.001
Systolic blood pressure, mm Hg	130 (22)	133 (20)	136 (22)	133 (21)	<0.001
Diastolic blood pressure, mm Hg	78 (13)	79 (12)	79 (13)	76 (12)	0.94
Hypertension, %	37.3	46.0	50.0	45.1	<0.001
ECG abnormalities, %	10.0	15.2	30.2	54.6	<0.001
Estimated GFR, mL/min per 1.73 m ²	84 (22)	85 (21)	82 (22)	72 (22)	<0.001
Chronic kidney disease, %	19.8	24.8	36.5	57.0	<0.001
Body mass index, kg/m ²	23.5 (3.6)	23.0 (3.4)	22.3 (3.6)	21.5 (3.5)	<0.001
Obesity, %	29.4	24.7	19.3	19.3	<0.001
Diabetes mellitus, %	16.9	16.0	21.4	17.6	0.58
Total cholesterol, mmol/L	5.45 (0.97)	5.17 (0.90)	5.04 (0.96)	4.81 (0.94)	<0.001
Hypercholesterolemia, %	35.3	25.3	23.5	10.6	<0.001
HDL cholesterol, mmol/L	1.60 (0.44)	1.64 (0.41)	1.64 (0.44)	1.64 (0.42)	0.10
Current drinking, %	44.1	43.2	43.0	31.8	0.95
Current smoking, %	21.0	24.2	23.1	21.8	0.32
Regular exercise, %	10.6	10.1	6.9	4.8	0.01

The mean age and frequency of men were not adjusted. All values are given as means (SD) or as percentages. NT-proBNP indicates N-terminal pro-brain natriuretic peptide; GFR, glomerular filtration rate; HDL, high-density lipoprotein.

*Hypertension: blood pressures of $\geq 140/90$ mm Hg or current use of antihypertensive medicine. Chronic kidney disease: estimated glomerular filtration rate < 60 mL/min per 1.73m² or a urine albumin-creatinine ratio of ≥ 30 mg/g. Obesity: body mass index ≥ 25 kg/m². Hypercholesterolemia: total cholesterol ≥ 5.69 mmol/L. Diabetes mellitus: fasting ≥ 7.0 mmol/L, 2-h postload or postprandial glucose levels ≥ 11.1 mmol/L, or use of hypoglycemic agents. ECG abnormalities: left ventricular hypertrophy (Minnesota Code 3-1), ST depression (4-1, 4-2, or 4-3), or atrial fibrillation (8-3).

Results

The baseline characteristics of the study population according to the 4 categories of NT-proBNP values are summarized in Table 1. The mean values of age and systolic blood pressure and the frequencies of hypertension, ECG abnormalities, and chronic kidney disease increased with increasing NT-proBNP levels, whereas the mean values of eGFR, BMI, and total cholesterol and the aggregation of each frequency of men, obesity, hypercholesterolemia, and regular exercise declined significantly with rising NT-proBNP levels.

Table 2 shows the age- and sex-adjusted incidence of CVD according to NT-proBNP levels. A significant association was observed between NT-proBNP levels and the incidence of total CVD. In regard to subtypes of CVD, the incidence of coronary heart disease and stroke increased significantly as the NT-proBNP levels increased. Similar findings were observed in stroke subtypes of ischemic stroke and intracerebral hemorrhage, but not subarachnoid hemorrhage. The HR for the development of total CVD increased with increasing NT-proBNP levels and was significantly higher even in subjects with NT-proBNP levels of 55 to 124 pg/mL compared with those with NT-proBNP levels of < 55 pg/mL after adjustment for age, sex, systolic blood pressure, ECG abnormalities, eGFR, BMI, diabetes, total and high-density lipoprotein cholesterol levels, smoking habits, alcohol intake, and regular exercise. Furthermore, when estimating the age- and

sex-adjusted and multivariate-adjusted HRs for a 1 SD increment in log-transformed NT-proBNP concentrations, we found significant upward trends for the development of total CVD and its subtypes (ie, coronary heart disease and stroke, including ischemic stroke and intracerebral hemorrhage), and the magnitude of the influence of the 1 SD increment in log NT-proBNP concentrations was almost equal among CVD subtypes (Table 2).

In the same way as the CVD incidence, the age- and sex-adjusted mortality from CVD increased with increasing NT-proBNP levels and was significantly higher in subjects with NT-proBNP levels of 125 to 399 pg/mL compared with those with the lowest NT-proBNP levels (Table 2). This association remained unchanged even after adjustment for the confounding factors mentioned above.

The age- and sex-adjusted HRs for the development of total CVD owing to a 1 SD increment in log NT-proBNP concentrations, in subjects with and without other cardiovascular risk factors, are shown in Figure 1. Comparable effects of a 1 SD increment in log NT-proBNP concentrations on the risk of total CVD were observed in subjects aged 40 to 64 years and those aged ≥ 65 years (P for heterogeneity=0.82). A sex difference in the influence of a 1 SD increment in log NT-proBNP concentrations on the incidence of CVD was identified, although the association between log NT-proBNP concentrations and the incidence of CVD was statically

Table 2. Adjusted Incidences, Mortalities, and Hazard Ratios of Cardiovascular Disease and Its Subtypes According to NT-proBNP Levels, 2002 to 2007

	NT-proBNP levels (pg/ml)				P for Trend (Across Categories)	Continuous Log Scale*	P for Trend (Continuous)
	<55 (n=1606)	55–124 (n=915)	125–399 (n=444)	≥400 (n=139)			
Total cardiovascular disease incidence							
No. of events/person-y	25/8304	37/4641	41/2082	24/542			
Age and sex incidence†	4.0	8.6	14.2	38.6			
Age- and sex-adjusted HR (95% CI)	1 (reference)	1.89 (1.10–3.24)	3.26 (1.83–5.80)	4.99 (2.55–9.74)	<0.001	1.71 (1.45–2.02)	<0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	1.85 (1.07–3.18)	2.98 (1.65–5.39)	4.54 (2.22–9.29)	<0.001	1.85 (1.51–2.27)	<0.001
Coronary heart disease							
No. of events/person-y	9/8339	16/4691	15/2150	9/574			
Age and sex incidence†	1.8	3.6	4.0	6.0			
Age- and sex-adjusted HR (95% CI)	1 (reference)	2.11 (0.88–5.05)	2.98 (1.16–7.67)	4.18 (1.41–12.42)	0.007	1.63 (1.25–2.13)	<0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	2.21 (0.92–5.30)	3.04 (1.15–8.04)	4.46 (1.38–14.39)	0.01	1.85 (1.33–2.57)	<0.001
Total stroke							
No. of events/person-y	16/8318	22/4656	30/2095	15/552			
Age and sex incidence†	2.2	5.2	10.9	31.9			
Age- and sex-adjusted HR (95% CI)	1 (reference)	1.77 (0.90–3.50)	3.81 (1.88–7.74)	5.20 (2.24–12.06)	<0.001	1.75 (1.43–2.14)	<0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	1.62 (0.82–3.21)	3.09 (1.49–6.41)	4.03 (1.65–9.87)	<0.001	1.79 (1.40–2.30)	<0.001
Ischemic stroke							
No. of events/person-y	8/8318	15/4656	20/2095	11/552			
Age and sex incidence†	1.2	3.6	6.8	29.0			
Age- and sex-adjusted HR (95% CI)	1 (reference)	2.26 (0.92–5.55)	4.54 (1.77–11.59)	6.61 (2.25–19.42)	<0.001	1.78 (1.39–2.28)	<0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	2.15 (0.87–5.35)	4.24 (1.62–11.09)	6.41 (2.04–20.20)	<0.001	1.97 (1.45–2.69)	<0.001
Intracerebral hemorrhage							
No. of events/person-y	4/8318	5/4656	7/2095	3/552			
Age and sex incidence†	0.6	1.1	3.3	2.1			
Age- and sex-adjusted HR (95% CI)	1 (reference)	2.16 (0.54–8.64)	5.71 (1.36–24.00)	7.04 (1.21–40.88)	0.009	1.87 (1.29–2.72)	0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	1.82 (0.45–7.37)	3.81 (0.88–16.50)	4.09 (0.64–26.07)	0.07	1.84 (1.12–3.02)	0.02
Subarachnoid hemorrhage							
No. of events/person-y	4/8318	2/4656	2/2095	1/552			
Age and sex incidence†	0.4	0.5	0.6	0.8			
Age- and sex-adjusted HR (95% CI)	1 (reference)	0.55 (0.09–3.36)	0.81 (0.11–6.19)	1.29 (0.10–17.53)	0.97	1.20 (0.54–2.65)	0.65
Multivariable-adjusted HR (95% CI)	1 (reference)	0.42 (0.07–2.60)	0.33 (0.04–2.94)	0.41 (0.02–6.77)	0.39	0.79 (0.31–2.00)	0.63
Cardiovascular disease mortality							
No. of events/person-y	2/8353	12/4709	16/2163	18/584			
Age and sex mortality†	0.5	2.4	6.2	12.3			
Age- and sex-adjusted HR (95% CI)	1 (reference)	3.91 (0.85–18.02)	5.25 (1.11–24.83)	12.70 (2.57–62.72)	<0.001	1.93 (1.46–2.56)	<0.001
Multivariable-adjusted HR (95% CI)	1 (reference)	4.08 (0.88–18.89)	5.60 (1.15–27.27)	12.87 (2.44–67.75)	<0.001	2.22 (1.57–3.14)	<0.001

Multivariable adjustment was made for age, sex, systolic blood pressure, electrocardiogram abnormalities, estimated glomerular filtration rate, body mass index, diabetes, total and high density lipoprotein cholesterol levels, smoking habits, alcohol intake, and regular exercise. NT-proBNP indicates N-terminal pro-brain natriuretic peptide; HR, hazard ratio.

*HR per 1 SD increase of log NT-proBNP.

†Per 1000 person-y.

significant in both sexes. There were no clear differences in the effects of NT-proBNP in subjects with and without other cardiovascular risk factors, such as hypertension, chronic kidney disease, obesity, diabetes, hypercholesterolemia, and smoking (all probability values for heterogeneity >0.05).

To evaluate the influence of NT-proBNP levels on the accuracy of CVD risk assessment, we compared the area under the ROC curve between models with and without NT-proBNP values (Figure 2). The area under the ROC curve was significantly increased by adding NT-proBNP values to the model including the potential risk factors mentioned above (from 0.820

to 0.841; *P* for difference in the area=0.006). The same was true for the respective CVD subtypes—ie, coronary heart disease and stroke (data not shown).

To compare the ability of NT-proBNP to predict future CVD with other risk factors, we estimated the areas under the ROC curves, adding continuous values of risk factors to the age- and sex-adjusted model. As a result, the area under the ROC curve was significantly larger for NT-proBNP (0.816) than for other risk factors, namely, systolic blood pressure (0.795), eGFR (0.784), BMI (0.782), total cholesterol (0.786), and high-density lipoprotein cholesterol (0.783) (all *P*<0.05).




Figure 1. Age- and sex-adjusted hazard ratios for the development of cardiovascular disease owing to a 1 SD increment in log NT-proBNP concentrations by the presence or absence of other cardiovascular risk factors. CKD indicates chronic kidney disease; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Discussion

In a prospective study of a general Japanese population, we clearly demonstrated that the risk for the development of CVD and its subtypes increased with increasing NT-proBNP levels and was significantly higher even in subjects with a modest increase in NT-proBNP. This association remained robust even after controlling for other confounding factors. The magnitude of the influence of NT-proBNP was nearly equal among CVD subtypes and larger than other risk factors. These findings suggest that high NT-proBNP levels are an independent and strong risk factor for the development of various types of CVD.

Several cohort studies have indicated that elevated BNP/NT-proBNP levels increased the risk of total CVD,⁶⁻¹¹ coronary heart disease,^{6,8,11} and stroke.^{6,7,9,11} However, very few prospective studies have provided evidence of associations between the natriuretic peptide levels and CVD in Asian populations.^{9,22} One cohort study of a Japanese population showed an association between increased BNP levels and the risk of developing ischemic stroke.⁹ Another clinical observational study in Japan also revealed a significant influence of elevated BNP levels on CVD events, but this association was not observed for coronary heart disease.²² The present study confirmed the results from the prior studies and provided more detailed information regarding the risks of various CVDs, including coronary heart disease and stroke. To the best of our knowledge, this is the first report to show that elevated NT-proBNP levels are an independent risk




Figure 2. Comparison of the accuracy of risk assessment for the development of cardiovascular disease. Model 1 includes age, sex, systolic blood pressure, ECG abnormalities, estimated glomerular filtration rate, body mass index, diabetes, total and high-density lipoprotein cholesterol levels, smoking habits, alcohol intake, and regular exercise. The area under the receiver operating characteristic curve was compared between model 1 alone and model 1 including NT-proBNP values. NT-proBNP indicates N-terminal pro-brain natriuretic peptide.

factor for the occurrence of intracerebral hemorrhage. In addition, in our study, a 1 SD increase in log NT-proBNP values was linked to an 85% increase in the total risk of CVD after adjustment for other traditional risk factors, and the magnitude of the influence of elevated log NT-proBNP concentrations was almost equal among CVD subtypes: namely, coronary heart disease, ischemic stroke, and intracerebral hemorrhage. In white population-based studies, a 1 SD increase in log NT-proBNP concentrations was associated with a 35% to 92% increase in the risk of major CVD events.^{6,7,11} These findings imply that the measurement of NT-proBNP values is valuable for identifying individuals at high risk of CVD independent of ethnicity.

In our study, NT-proBNP levels were inversely related to obesity and hypercholesterolemia and positively related to age and blood pressure levels and the prevalence of chronic kidney disease. Nevertheless, the inclusion of these factors in the model did not attenuate the overall association between NT-proBNP levels and total CVD, and adding NT-proBNP values to potential risk factors significantly increased the area under the ROC curve. Furthermore, our study revealed no interactions between the various risk factors and NT-proBNP values, with the exception of sex. These findings imply that NT-proBNP is a novel and universal risk factor for various

types of CVD and may improve the risk prediction of future CVD events in general populations beyond the estimation afforded by classical risk factors.

The mechanisms underlying the association between natriuretic peptides and the risks of CVDs are still unknown. A cross-sectional study found that high NT-proBNP levels were independently associated with higher coronary artery calcium scores as evaluated by electron beam computed tomography in subjects without heart failure or renal dysfunction.²³ This fact raises the possibility that BNP/NT-proBNP levels are correlated with the degree of systemic atherosclerosis. Because elevated natriuretic peptides reflect increased ventricular stretch from volume as well as pressure overloads,² subjects with these overloads might have vascular stretch and wall tension, which could contribute to the development of CVD. However, NT-proBNP levels are considered a surrogate marker because medication with BNP has an effect on relaxation, but not on tension, of the human arteries.^{24–25} To date, no specific pathological role of natriuretic peptides has been identified in inflammation, oxidative stress, or abnormalities in coagulation and fibrinolytic pathways, which are considered to be the major pathological mechanisms involved in the atherosclerotic process. Additional studies are needed to reveal the mechanisms of the association between NT-proBNP levels and vascular damage.

The strengths of our study include its longitudinal population-based design, low selection bias, perfect follow-up of subjects, and accuracy of diagnosis of CVD subtypes. One limitation of our study is that the evaluation of NT-proBNP values was based on a single measurement at baseline, as is the case in most epidemiological studies. During the follow-up, the levels were changed because of modifications in lifestyle or medication, and misclassification of NT-proBNP levels was possible. This could have weakened the association found in this study, biasing the results toward the null hypothesis. Therefore, the true association may be stronger than that shown in our study.

In conclusion, the present analysis clearly showed that elevated NT-proBNP levels were a novel risk factor for CVD and its subtypes—ie, coronary heart disease and stroke—in a general population of Japanese. This study also demonstrated the potential applicability of NT-proBNP measurement to epidemiological studies; such an approach may be suitable for large-scale screening programs to evaluate the risk of CVD, including coronary heart disease and stroke.

Acknowledgments

We thank the staff of the Division of Health and Welfare of Hisayama for their cooperation in this study.

Sources of Funding

This study was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas (22116010) and C (20591063, 21590698, and 22590892) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a Health and Labour Sciences Research Grant of the Ministry of Health, Labour

and Welfare of Japan (Comprehensive Research on Aging and Health: H20-Chouju-004).

Disclosures

None.

References

- Daniels LB, Maisel AS. Natriuretic peptides. *J Am Coll Cardiol*. 2007; 50:2357–2368.
- Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *N Engl J Med*. 1998;339:321–328.
- Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J*. 2008;29:2388–2442.
- Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storror AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. *Circulation*. 2007;115:e356–e375.
- Ribeiro AL. Natriuretic peptides in elderly people with acute myocardial infarction. *BMJ*. 2009;338:b787.
- Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasani RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–663.
- Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA*. 2005;293:1609–1616.
- Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. *JAMA*. 2009;302:49–57.
- Takahashi T, Nakamura M, Onoda T, Ohsawa M, Tanno K, Itai K, Sakata K, Sakuma M, Tanaka F, Makita S, Yoshida Y, Ogawa A, Kawamura K, Okayama A. Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. *Atherosclerosis*. 2009;207:298–303.
- Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. *Eur Heart J*. 2010;31:120–127.
- Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Wittman JC, van den Meiracker AH. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam Study. *Hypertension*. 2010;55:785–791.
- Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiya K, Ohmori S, Yoshitake T, Shinkawa A, Hasuo Y, Fujishima M. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. *Diabetologia*. 1993;36:1198–1203.
- Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Arima H, Hata J, Tanizaki Y, Iida M, Kiyohara Y. Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. *J Clin Endocrinol Metab*. 2008;93:3425–3429.
- Kubo M, Hata J, Doi Y, Tanizaki Y, Iida M, Kiyohara Y. Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. *Circulation*. 2008;118:2672–2678.
- Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke*. 1990;21:637–676.
- Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche